Tag : cefiderocol

Latest News

Shionogi riferisce risultati positivi di uno studio di fase III su cefiderocol negli adulti con polmonite nosocomiale causata da agenti patogeni Gram-negativi

Newsemia
AMSTERDAM, Paesi Bassi–(BUSINESS WIRE)–Shionogi & Co., Ltd. (di seguito “Shionogi”) ha reso noti i risultati di APEKS-NP, uno studio clinico internazionale di fase III randomizzato...
Latest News

Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens

Newsemia
OSAKA, Japan & AMSTERDAM–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.) and Shionogi B.V. the European subsidiary of...
Pharma / Biotech

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Newsemia
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs. 2019 Feb 02;: Authors: Zhanel GG, Golden AR, Zelenitsky S, Wiebe K,...
Gastroenterology

The Lancet Infectious Diseases journal publishes clinical trial results for Shionogi’s cefiderocol

Newsemia
Shionogi & Co., Ltd. announced today that The Lancet Infectious Diseases journal has published clinical results from the pivotal randomized controlled trial evaluating cefiderocol for...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy